| Overview |
| bs-1499R-HRP |
| SUMO 1 Polyclonal Antibody, HRP Conjugated |
| WB, ELISA, IHC-P, IHC-F |
| There is a chance that this antibody will cross-react with SUMO13 |
| Mouse, Rat |
| Human, Cow, Pig, Horse, Chicken |
| Specifications |
| HRP |
| Rabbit |
| KLH conjugated synthetic peptide derived from human SUMO 1 |
| 21-101/101 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7341 |
| P63165 |
| Cytoplasm, Nucleus, Cell membrane |
| Small ubiquitin-related modifier 1; SUMO-1; GAP-modifying protein 1; GMP1; SMT3 homolog 3; Sentrin; Ubiquitin-homology domain protein PIC1; Ubiquitin-like protein SMT3C; Smt3C; Ubiquitin-like protein UBL1; SUMO1; SMT3C; SMT3H3; UBL1; OK/SW-cl.43 |
| Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
Powered by Bioz